Nader Halim, Innervace CEO

Deer­field backs a Penn spin­out aim­ing to shake up Parkin­son's treat­ments us­ing stem cells, brain surgery

Un­like in oth­er neu­rode­gen­er­a­tive dis­eases, such as Alzheimer’s, the pathol­o­gy of Parkin­son’s is rel­a­tive­ly well-un­der­stood. Re­searchers have known for decades that the dis­ease af­fects the brain’s pro­duc­tion of dopamine, where­as Alzheimer’s has flum­moxed those in­ves­ti­gat­ing amy­loid and oth­er once-promis­ing the­o­ries.

But the broad­er depth of knowl­edge has still yet to trans­late in­to new­er, more ef­fec­tive ther­a­pies. Af­ter the FDA ap­proved Sinemet in the 1970s, a com­bi­na­tion of two drugs de­signed to con­vert in­to dopamine in the brain (and main­tain that con­ver­sion), the prod­uct re­mains pa­tients’ pri­ma­ry ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.